Thomas Burruss Hudson

US Patent:

20040053950, Mar 18, 2004

Filed:

Jun 20, 2003

Appl. No.:

10/600446

Inventors:

Suping Jiang - Potomac MD, US
Thomas Hudson - Bethesda MD, US
Wilbur Milhous - Germantown MD, US

International Classification:

A61K031/517

US Classification:

514/266220

Abstract:

Malaria is the most severe tropical parasitic disease that has caused millions of deaths in many countries. The threat of growing drug-resistant parasites requires development of new antimalarial drugs to overcome the emergence of resistance and to control the disease. Febrifugine is the active principle extracted from the Chinese herb Chang Shan (Lour) that has been used to treat malaria for more than two thousand years. Studies on the efficacy have been hindered due to the emetic effects of febrifugine. The present invention discloses febrifugine, halofuginone and febrifugine derivatives for use as antimalarial agents without the severe emetic effects observed in direct herbal use.

US Patent:

51126079, May 12, 1992

Filed:

Jun 5, 1991

Appl. No.:

7/715094

Inventors:

Thomas H. Hudson - Bethesda MD
Michael A. King - Laurel MD

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

A61K 3939
A61K 39395

US Classification:

424 8591

Abstract:

A method of potentiating immunotoxin action in an immunotoxin/target-cell stem in which Brefeldin A is utilized as an immunopotentiator. The Brefeldin A enhances the immunotoxin pathway while blocking or inhibiting the nonspecific pathway, thus being particularly useful in conjunction with immunotoxins made from holotoxins. The Brefeldin A is effective in small, nontoxic concentrations and therefore may be utilized with either in vivo or in vitro systems.